Clinical Research Papers:

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Shencun Fang, Meiling Zhang, Guihong Wei and Kai-Hua Lu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:7175-7181. https://doi.org/10.18632/oncotarget.23612

Metrics: PDF 1000 views  |   HTML 1503 views  |   ?  


Shencun Fang1,3,*, Meiling Zhang2,*, Guihong Wei3 and Kai-Hua Lu2

1Department of Respiratory Medicine Center, Nanjing Chest Hospital, Nanjing, Jiangsu, China

2Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

3Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

*These authors contributed equally to this work

Correspondence to:

Kai-Hua Lu, email: lu_kaihua@sohu.com

Keywords: non-small-cell lung cancer; angiogenesis; apatinib; VEGFR-2

Received: August 24, 2017     Accepted: November 14, 2017     Published: December 22, 2017


Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy.

Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors.

Results: 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status (p = 0.015). Most adverse reactions were mild or moderate.

Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23612